Long-acting anti-NGF mAb therapy
搜索文档
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
Businesswire· 2025-09-13 00:09
公司动态 - 公司旗下药物Portela如获批将成为首个用于猫科动物的长效抗神经生长因子单克隆抗体疗法 [1] - 该疗法旨在提供长达3个月的骨关节炎疼痛缓解效果 [1]
